Zenith Technologies appoints serialization director
The appointment comes as the pharmaceutical industry faces the challenge of complying with new legal requirements for the authentication and barcoding of licensed drug products.
A global life science technology firm, with headquarters in Ireland, has appointed Carlos Machado as serialization director to lead the company’s sales, operations, implementation and post project support services in the US.
The appointment comes as the pharmaceutical industry faces the challenge of complying with new legal requirements for the authentication and barcoding of licensed drug products from November 2017 in the US and early 2019 in Europe.
Carlos joins Zenith Technologies with significant experience of assisting pharmaceutical manufacturers with track and trace technologies, having worked on more than 75 serialization projects from both an operations and delivery perspective.
In his former role as director of global operations at a leading anti-counterfeiting technology provider, Carlos helped to pioneer the serialization concept and define the future of authentication.
Jim Lehane, director at Zenith Technologies, said: “Serialization is a real challenge for our customers and it’s an important time for us to add further expertise to our team. Carlos’ background in track and trace technologies and his knowledge of the implementation challenges pharmaceutical manufacturers face, make him ideally suited to lead our serialization offering in the US, helping our customers achieve seamless compliance with the new regulations.
“Zenith Technologies has strong partnerships with many of the world’s largest pharmaceutical manufacturers as well as life science companies of all sizes, providing automation consulting and local support services. Carlos’ appointment will help us to take our US offering to the next level.”
Commenting on his appointment, Carlos said: “Serialization is a huge priority for Zenith Technologies as we understand the challenges customers face in addressing supply chain security and preventing the introduction and distribution of counterfeit product into the global marketplace. It is an exciting time to join the firm as we expand our US presence, leveraging our technological experience, sound project management practices, skilled engineers and world-class implementation and support services.
“When it comes to complying with new serialization regulations, the industry, ranging from the top pharmaceutical companies to contract manufacturing organizations (CMOs), understands what needs to be done. The challenge lies in the scale and complexity of the task ahead. In my new position, it is my responsibility to draw on my industry experience and work alongside our customers to simplify the implementation process and provide flawless execution.”
The announcement is the next stage in Zenith Technologies’ goal to assist companies in the US and Europe with the challenge of serialization. The company recently announced a global partnership with software provider SEA Vision to support pharmaceutical companies with the installation and integration of serialization solutions across drug manufacturing sites.
Carlos continued: “Given our combined expertise and remarkable track record, it’s a natural marriage. We will be working exclusively with SEA Vision to improve existing processes and delivery time, implement its technology and systems and enhance the overall customer experience.
“Our organizations are also working towards providing an innovative interactive e-learning environment to assist our customers with serialization training. We are also actively recruiting and adding experienced talent to our serialization taskforce in the US to ensure we can continue to deliver a high level of service at a local level.”
Marco Baietti, commercial director at SEA Vision said: “Carlos provides a unique combination of leadership skills and expertise in the serialization field thanks to his specialist background. We are thrilled to welcome him to the team and look forward to working together to deliver our shared goal to provide the best track & trace solutions and services in the markets that we serve.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance